Stomach Stapling Paves A Pathway

Emily BurkeBiologics, Clinical Trials, Diabetes, Drug Development, Drug Targets, Mechanism of Action, The WEEKLY

Identifying Gut Proteins To Tackle Metabolic Disorders Historians of science love to tell about “eureka moments”—simple observations leading to major insight. Greek mathematician Archimedes allegedly exclaimed the original “Eureka!”—meaning “I have found it!”—upon witnessing the volume of water displaced by his body in the bathtub equaled the volume of the body part he had submerged. Medicine’s most famous eureka moment is probably the … Read More

Finding Footprints

Emily BurkeBiotech Basics, Cancer, Deoxyribonucleic Acid (DNA), Diagnostics, Genetics, Monoclonal Antibodies, Term of the Week, The WEEKLY

New Player In Cancer Biomarker Detection Catching a tumor’s first footprints is the holy grail of cancer research. The ability to detect and treat cancer early would put the collective mind of humanity at ease. Our best bet yet is the liquid biopsy—a minimally invasive test to detect and monitor cancer, which happens to be all the rage in cancer diagnostics. Liquid biopsies … Read More

Drugging The Undruggable

Emily BurkeBiotech Basics, Business of Biotech, Drug Development, Drug Targets, Mechanism of Action, Ribonucleic Acid (RNA), Small Molecule Drugs, Term of the Week, The WEEKLY

Antagonists Fight A Good Fight Small molecule inhibitors, also known as antagonists in the industry, fight a good fight. In fact, many drugs on the market today work by inhibiting overactive, disease-associated proteins. Novartis’ (Basel, Switzerland) top selling leukemia drug Gleevec, for example, is a small molecule inhibitor of a protein called Bcr-Abl, whose overactivity promotes excessive cell division. The downside? It is … Read More